Godavari Biorefineries Ltd shareholders have approved the re-appointment of Mr Nitin Mehta and Dr Sangeeta Srivastava as directors through a postal ballot process. The resolutions, which sought to re-appoint Mr Nitin Mehta as an Independent Director and Dr Sangeeta Srivastava as a Whole Time Director designated as an Executive Director, received the requisite majority. This decision ensures continuity in the company's leadership structure as it moves forward with its operational strategies.

The remote e-voting facility was open from 9:00 a.m. (IST) on Friday, May 29, 2026, until 5:00 p.m. (IST) on Sunday, June 28, 2026. A total of 89,597 shareholders were eligible to vote as of the record date of Friday, May 15, 2026. The voting process was scrutinized by Tushar Shridharani, a Practicing Company Secretary from Tushar Shridharani & Associates LLP, who was appointed by the Board on May 22, 2026.

Voting Results

Both resolutions were classified as special resolutions and required approval from members. The scrutinizer's report detailed the voting patterns across different shareholder categories, including Promoter and Promoter Group, Public Institutions, and Public Non-Institutions. The results indicated strong support from the promoter group and public institutions.

For the re-appointment of Mr Nitin Mehta, the total number of votes polled stood at 37,958,281, representing 74.17% of the total outstanding shares. The resolution passed with 99.99% of the votes polled in favour. Similarly, the resolution for Dr Sangeeta Srivastava saw 37,958,131 votes polled, accounting for 74.17% of the outstanding shares, with 99.99% of the votes cast in favour.

Scrutinizer's Report

Tushar Shridharani & Associates LLP confirmed that the postal ballot notice was sent in compliance with the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report noted that the e-voting module was disabled by NSDL, the service provider, upon the expiry of the voting period. The scrutinizer validated the votes and declared the resolutions passed.

The detailed voting results show that the Promoter and Promoter Group cast 32,400,110 votes in favour of both resolutions, with zero votes against. Public Institutions cast 4,995,317 votes in favour, while Public Non-Institutions cast 560,113 and 560,092 votes in favour for the first and second resolutions, respectively. The company has hosted the full report on its website.

Godavari Biorefineries Ltd has been granted a patent by the Japanese Patent Office for its invention, "5-Hydroxy-1,4-naphthalenedione for use in the treatment of cancer." The patent, numbered 7869786, was registered on May 26, 2026, and covers a novel class of compounds that exhibit strong inhibitory effects on cancer and cancer stem cells. This development strengthens the company's intellectual property portfolio in the biotechnology and pharmaceutical domain.

Patent Grant Details

The patent application, numbered 2023-525533, was originally filed on October 26, 2021. The inventors listed on the patent include Sandeep Gawade, Sangeeta Srivastava, Prashant Karkal, and Maithili Atavale. The patent specifically addresses the compound's efficacy against multiple types of cancer, including breast and prostate cancer.

Significance of the Development

Receiving the patent from Japan represents formal recognition of the novelty and inventiveness of Godavari Biorefineries Ltd's cancer treatment compound. Patents in the pharmaceutical and biotechnology sectors serve as critical markers of innovation, providing the company with exclusive intellectual property rights over the compound in the Japanese jurisdiction. The acknowledgment of the compound's strong effects on cancer and stem cells highlights its scientific distinction within the oncology space.